

News Releases

All Years



Search

GO

[Advanced Search](#)

Jul 2, 2013

Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R)

Data Presented in Oral Session at 2013 Congress of the International Society on Thrombosis and Haemostasis

AMSTERDAM, THE NETHERLANDS and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/02/13 -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced positive pharmacodynamic and safety data from a...

Jun 26, 2013

Portola Announces Oral Presentation of Phase 2 Data on PRT4445, Factor Xa Inhibitor Antidote, at 2013 International Society on Thrombosis and Haemostasis Congress

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/26/13 -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that safety and pharmacodynamic data from a Phase 2 trial of its...

Jun 26, 2013

Portola and Daiichi Sankyo Enter into Clinical Collaboration Agreement for Phase 2 Study of PRT4445 and Edoxaban

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/26/13 -- Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that it has entered into a clinical collaboration agreement with Daiichi Sankyo...

Jun 12, 2013

Portola Pharmaceuticals to Present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2013) - Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that William Lis, chief executive officer, will present at the Wells Fargo...

May 28, 2013

Portola Announces Closing of Initial Public Offering and Over-Allotment Option Exercise

SOUTH SAN FRANCISCO, CA - (May 28, 2013) - Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) announced today the closing of its initial public offering of 9,686,171 shares of its common stock at a...

Show 5



per

< [1](#) ... [41](#) [42](#) [43](#) [44](#) [45](#) [46](#) [47](#) [48](#) [49](#) >

page



<https://investors.portola.com/news-releases?o=235>